Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Energy Services Reunited Corp Ordinary Shares (NESR) vs GeneDx Holdings Corp (WGS) Price & Performance

National Energy Services Reunited Corp Ordinary SharesTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

National Energy Services Reunited Corp Ordinary Shares vs GeneDx Holdings Corp — how do they compare? National Energy Services Reunited Corp Ordinary Shares trades at $19.5 (market cap $1.97B), while GeneDx Holdings Corp trades at $68.61 (market cap $2.04B). The key difference: National Energy Services Reunited Corp Ordinary Shares and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is more actively traded (962,082 versus 4,629,858). Which is the better fit depends on your goals — on Pluang, investors hold National Energy Services Reunited Corp Ordinary Shares for 0 Days and GeneDx Holdings Corp for 20 Days on average.

NESRWGS
Market Cap
$1.97B$2.04B
Volume
4,629,858962,082
Sector
EnergyHealth
52-Week High
$36.31$167.51
52-Week Low
$10.41$34.51
Typical Hold Time
0 Days20 Days
Enterprise Value
$2.10B$2.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Energy Services Reunited Corp Ordinary Shares

NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.

The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.

The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NESR
100% Buy0% Sell
Avg holding period · 0 Days
WGS
100% Buy0% Sell
Avg holding period · 20 Days

About National Energy Services Reunited Corp Ordinary Shares

National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.

Read more on NESR →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →